Edition:
India

Evolus Inc (EOLS.OQ)

EOLS.OQ on NASDAQ Stock Exchange Global Market

18.48USD
1:30am IST
Change (% chg)

$-0.52 (-2.74%)
Prev Close
$19.00
Open
$19.05
Day's High
$19.42
Day's Low
$17.72
Volume
224,404
Avg. Vol
202,811
52-wk High
$30.25
52-wk Low
$10.29

Latest Key Developments (Source: Significant Developments)

Alphaeon Corporation Sells 4 Million Shares In Evolus Inc
Thursday, 16 May 2019 

May 15 (Reuters) - Alphaeon Corporation::PRESS RELEASE - ALPHAEON CORPORATION SELLS 4 MILLION SHARES IN EVOLUS INC..  Full Article

Evolus Q1 Loss Per Share $0.40
Wednesday, 1 May 2019 

April 30 (Reuters) - Evolus Inc ::EVOLUS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.40.Q1 EARNINGS PER SHARE ESTIMATE $-0.79 -- REFINITIV IBES DATA.  Full Article

Evolus Provides Regulatory Update On Nuceiva In The European Union
Monday, 1 Apr 2019 

April 1 (Reuters) - Evolus Inc ::EVOLUS PROVIDES REGULATORY UPDATE ON NUCEIVA™ IN THE EUROPEAN UNION.EVOLUS - EXPECTS EMA TO ADOPT A FORMAL OPINION ON NUCEIVA MARKETING AUTHORIZATION APPLICATION (MAA) DURING APRIL 2019 COMMITTEE MEETING.  Full Article

Evolus Reports Q4 Loss Per Share $0.46
Tuesday, 19 Mar 2019 

March 18 (Reuters) - Evolus Inc ::EVOLUS REPORTS FOURTH QUARTER AND FULL YEAR 2018 RESULTS.Q4 LOSS PER SHARE $0.46.Q4 EARNINGS PER SHARE ESTIMATE $-0.55 -- REFINITIV IBES DATA.  Full Article

Evolus Secures $100 Million Senior Debt Facility With Oxford Finance Llc
Tuesday, 19 Mar 2019 

Evolus Inc ::EVOLUS SECURES $100 MILLION SENIOR DEBT FACILITY WITH OXFORD FINANCE LLC.EVOLUS INC - UNDER TERMS OF AGREEMENT, AN INITIAL TRANCHE OF $75 MILLION WAS FUNDED AT CLOSING.EVOLUS INC - REQUIRED TO MAKE INTEREST ONLY PAYMENTS ON A MONTHLY BASIS THROUGH APRIL 2022.EVOLUS INC - ENTIRE SENIOR DEBT FACILITY WILL MATURE ON MARCH 1, 2024.  Full Article

Evolus Receives FDA Approval For Jeuveau Prabotulinumtoxina-XVFS For Injection
Saturday, 2 Feb 2019 

Feb 1 (Reuters) - Evolus Inc ::EVOLUS RECEIVES FDA APPROVAL FOR JEUVEAU™ PRABOTULINUMTOXINA-XVFS FOR INJECTION.EVOLUS INC - JEUVEAU LAUNCH PLANNED IN SPRING 2019.EVOLUS INC - JEUVEAU MAY CAUSE SERIOUS SIDE EFFECTS THAT CAN BE LIFE THREATENING.EVOLUS INC - JEUVEAU MAY CAUSE SERIOUS SIDE EFFECTS SUCHS AS PROBLEMS SWALLOWING, SPEAKING, OR BREATHING AND SPREAD OF TOXIN EFFECTS.  Full Article

Evolus Receives Conditional FDA Acceptance Of Jeuveau Brand Name
Monday, 19 Nov 2018 

Nov 19 (Reuters) - Evolus Inc ::EVOLUS RECEIVES CONDITIONAL FDA ACCEPTANCE OF JEUVEAU BRAND NAME.EVOLUS INC - IN COMING MONTHS, EVOLUS PLANS TO ACCELERATE ITS TRANSITION FROM AN RESEARCH AND DEVELOPMENT TO A COMMERCIAL STAGE COMPANY.  Full Article

Evolus Receives Acceptance Of FDA BLA Resubmission For Dwp-450
Wednesday, 29 Aug 2018 

Aug 29 (Reuters) - Evolus Inc ::EVOLUS RECEIVES ACCEPTANCE OF FDA BLA RESUBMISSION FOR DWP-450.EVOLUS INC - FDA CONSIDERED RESUBMISSION A CLASS 2 RESPONSE AND HAS ASSIGNED A FEBRUARY 2, 2019 ACTION DATE PER PRESCRIPTION DRUG USER FEE ACT.  Full Article

Evolus Announces Update With DWP-450 Regulatory Submissions
Wednesday, 16 May 2018 

May 16 (Reuters) - Evolus Inc ::EVOLUS ANNOUNCES PROGRESS WITH DWP-450 REGULATORY SUBMISSIONS.EVOLUS INC - CONFERENCE CALL SCHEDULED FOR 8:30AM ET / 5:30AM PT.EVOLUS INC - EVOLUS RECEIVES FDA COMPLETE RESPONSE LETTER WITH COMMENTS ISOLATED TO CMC ITEMS.EVOLUS INC - PLANS TO UTILIZE DAEWOONG FACILITY TO SUPPORT COMMERCIAL PRODUCTION FOLLOWING ANTICIPATED APPROVAL OF DWP-450..EVOLUS INC - FDA ISSUES FAVORABLE EIR LETTER RELATED TO MANUFACTURING FACILITY.EVOLUS INC - DWP-450 MANUFACTURING FACILITY IS FULLY VALIDATED BY DAEWOONG UNDER CURRENT GOOD MANUFACTURING PRACTICE REQUIREMENTS.EVOLUS INC - IN CRL, DEFICIENCIES CITED BY FDA WERE ISOLATED TO ITEMS RELATED TO CHEMISTRY, MANUFACTURING, AND CONTROLS PROCESSES.EVOLUS INC - EXPECTS TO RESPOND TO FDA ABOUT CRL WITH A COMPLETE SUBMISSION TO FDA WITHIN 90 DAYS.EVOLUS INC - LOOK FORWARD TO WORKING CLOSELY WITH FDA AND REMAIN COMMITTED TO BRINGING DWP-450 TO MARKET BY SPRING 2019.EVOLUS INC - DWP-450 MANUFACTURING FACILITY HAS CAPACITY EXPECTED TO MEET ANTICIPATED PRODUCT DEMAND.  Full Article

Evolus Reports Q1 Loss Per Share $0.30
Friday, 11 May 2018 

May 10 (Reuters) - Evolus Inc ::EVOLUS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.30.Q1 EARNINGS PER SHARE VIEW $-0.24 -- THOMSON REUTERS I/B/E/S.  Full Article

Photo

FDA approves cheaper Botox rival to treat frown lines

(This Feb. 1 story has been corrected to remove reference to dosage in paragraph 7)